Bristol Myers Squibb Tops Q4 Estimates

Biopharmaceutical giant Bristol Myers Squibb (NYSE:BMY) reported fourth-quarter and full-year 2024 earnings on Thursday, Feb. 6, that topped analysts' consensus estimates. Adjusted earnings per share (EPS) of $1.67 outperformed the anticipated $1.46 while Q4 revenue surged to $12.3 billion, surpassing the estimate of $11.57 billion.

The quarter's results, reaffirmed Bristol Myers Squibb's financial health and strategic focus despite ongoing competition from generics manufacturers impacting its legacy portfolio of drugs.

Source: Bristol Myers Squibb. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. Adjusted figures are non-GAAP (generally accepted accounting principles).

Overview of Bristol Myers Squibb

Bristol Myers Squibb is a prominent entity in the biopharmaceutical sector, concentrating on innovative medicines that meet unmet medical needs across oncology, cardiovascular, and immunology domains. Recently, it has intensely focused on expanding its product portfolio and securing market exclusivity through strategic R&D efforts. Key success factors encompass advances in its product pipeline, managing patent expirations, and strategic collaborations.

Core to its strategy, Bristol Myers Squibb actively invests in the development of new molecular entities, alongside strategically acquiring companies to amplify its R&D capabilities. This approach nurtures its position in highly competitive sectors, ensuring ongoing innovation to stay at the forefront of the pharmaceutical industry.

Quarterly Highlights and Developments

Throughout the quarter, Bristol Myers Squibb reported notable financial and operational achievements. Its Growth Portfolio revenue increased significantly by 21%, reaching $6.4 billion. This surge was driven by strong demand for key drugs such as Reblozyl, Breyanzi, and Camzyos, which saw respective growth of 71%, 125%, and 101% year over year. Meanwhile, the Legacy Portfolio faced challenges, with a 4% decline as generic competition impacted products like Sprycel and Revlimid, though Eliquis cushioned these effects with its 11% growth.

The company celebrated significant milestones in its product pipeline, notably the FDA approval of Cobenfy and the promising regulatory path of Opdivo-related treatments. These achievements underscore Bristol Myers Squibb's commitment to advancing its pipeline in therapeutic areas with significant unmet needs. Furthermore, GAAP gross margin fell due to intangible asset impairments but maintained a strong non-GAAP margin of 74%.

Bristol Myers Squibb continues to make strides in strategic initiatives to secure long-term growth. It aims for $2 billion in savings by 2027, optimizing its operational efficiency. Additionally, it remains committed to its robust R&D investment strategy, with a 29% increase in its GAAP R&D expenses in Q4, highlighting its growth-focused trajectory.

Outlook for the Future

For 2025, Bristol Myers Squibb projects revenue of roughly $45.5 billion, with a non-GAAP EPS between $6.55 and $6.85. Those estimates came in below analysts' consensus projections of a profit of $6.91 per share and $46.29 billion in sales. Management's strategic emphasis remains on mitigating legacy portfolio declines and leveraging the growth potential of newer assets. The company anticipates notable impacts from generic competitors, but strong performances from its growth portfolio are expected to offset these pressures.

Given the recent developments, investors are encouraged to focus on Bristol Myers Squibb's progress in expanding its product line and pipeline advancements. The management's priority on strategic investments and operational efficiency remains crucial for ongoing competitive success. Key areas to watch include regulatory updates and further pipeline advancements, crucial for sustaining growth in the coming quarters.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 921% — a market-crushing outperformance compared to 177% for the S&P 500.*

They just revealed what they believe are the 10 best stocks for investors to buy right now…

Learn more »

*Stock Advisor returns as of February 3, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.